{
  "trial_id": "NCT02731729",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ethnicity, Eastern Cooperative Oncology Group (ECOG) performance status, Karnofsky Performance Status, stage of melanoma, prior treatments, time since last PD-1/PD-L1 therapy, measurable disease status, organ and marrow function parameters (white blood cells, absolute neutrophil count, platelets, hemoglobin, total bilirubin, AST/ALT levels, serum creatinine), life expectancy, pregnancy status, contraception use, history of autoimmune disease, history of other malignancies, history of brain metastases, HIV/HBV/HCV status, history of allergy to study drug components.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "ECOG Performance Status",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Type of Melanoma",
          "stage of melanoma"
        ],
        [
          "Prior Treatment",
          "prior treatments"
        ],
        [
          "Median time since last anti-PD-1 treatment",
          "time since last PD-1/PD-L1 therapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "M stage",
        "Genomic Driver",
        "Best response to prior anti-PD-1 treatment",
        "Median lactate dehydrogenase"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "Karnofsky Performance Status",
        "measurable disease status",
        "organ and marrow function parameters (white blood cells, absolute neutrophil count, platelets, hemoglobin, total bilirubin, AST/ALT levels, serum creatinine)",
        "life expectancy",
        "pregnancy status",
        "contraception use",
        "history of autoimmune disease",
        "history of other malignancies",
        "history of brain metastases",
        "HIV/HBV/HCV status",
        "history of allergy to study drug components."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Eastern Cooperative Oncology Group (ECOG) performance status, White blood cells, Absolute neutrophil count, Platelets, Hemoglobin, Total bilirubin, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Serum creatinine, Prior anti-PD-1 therapy response, Measurable disease status, Histologic proof of melanoma, Life expectancy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "ECOG Performance Status",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Prior Treatment",
          "Prior anti-PD-1 therapy response"
        ]
      ],
      "remaining_reference_features": [
        "M stage",
        "Type of Melanoma",
        "Genomic Driver",
        "Best response to prior anti-PD-1 treatment",
        "Median lactate dehydrogenase",
        "Median time since last anti-PD-1 treatment"
      ],
      "remaining_candidate_features": [
        "White blood cells",
        "Absolute neutrophil count",
        "Platelets",
        "Hemoglobin",
        "Total bilirubin",
        "Aspartate aminotransferase (AST)",
        "Alanine aminotransferase (ALT)",
        "Serum creatinine",
        "Measurable disease status",
        "Histologic proof of melanoma",
        "Life expectancy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Karnofsky Performance Status, Prior PD-1 Inhibitor Therapy, Time from Last Dose of PD-1 Inhibitor, Best Response to Prior PD-1 Inhibitor, Number of Prior Systemic Therapies, Presence of Brain Metastases, LDH Level, S100B Level.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "ECOG Performance Status",
          "ECOG Performance Status"
        ],
        [
          "Prior Treatment",
          "Prior PD-1 Inhibitor Therapy"
        ],
        [
          "Best response to prior anti-PD-1 treatment",
          "Best Response to Prior PD-1 Inhibitor"
        ],
        [
          "Median lactate dehydrogenase",
          "LDH Level"
        ],
        [
          "Median time since last anti-PD-1 treatment",
          "Time from Last Dose of PD-1 Inhibitor"
        ]
      ],
      "remaining_reference_features": [
        "Region of Enrollment",
        "M stage",
        "Type of Melanoma",
        "Genomic Driver"
      ],
      "remaining_candidate_features": [
        "Karnofsky Performance Status",
        "Number of Prior Systemic Therapies",
        "Presence of Brain Metastases",
        "S100B Level"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, Eastern Cooperative Oncology Group performance status, Karnofsky Performance Status, American Joint Committee on Cancer (AJCC) stage, measurable disease, histologic proof of melanoma, previous treatment with PD-1 or PD-L1 inhibitor, time from last dose of PD-1 blocking antibody, life expectancy, white blood cells, absolute neutrophil count, platelets, hemoglobin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, serum creatinine, creatinine clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "ECOG Performance Status",
          "Eastern Cooperative Oncology Group performance status"
        ],
        [
          "M stage",
          "American Joint Committee on Cancer (AJCC) stage"
        ],
        [
          "Prior Treatment",
          "previous treatment with PD-1 or PD-L1 inhibitor"
        ],
        [
          "Median time since last anti-PD-1 treatment",
          "time from last dose of PD-1 blocking antibody"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Type of Melanoma",
        "Genomic Driver",
        "Best response to prior anti-PD-1 treatment",
        "Median lactate dehydrogenase"
      ],
      "remaining_candidate_features": [
        "ethnicity",
        "Karnofsky Performance Status",
        "measurable disease",
        "histologic proof of melanoma",
        "life expectancy",
        "white blood cells",
        "absolute neutrophil count",
        "platelets",
        "hemoglobin",
        "total bilirubin",
        "aspartate aminotransferase",
        "alanine aminotransferase",
        "serum creatinine",
        "creatinine clearance"
      ]
    }
  }
}